Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Current Assets (2016 - 2025)

Ligand Pharmaceuticals' Current Assets history spans 16 years, with the latest figure at $832.3 million for Q4 2025.

  • For Q4 2025, Current Assets rose 151.02% year-over-year to $832.3 million; the TTM value through Dec 2025 reached $832.3 million, up 151.02%, while the annual FY2025 figure was $832.3 million, 151.02% up from the prior year.
  • Current Assets for Q4 2025 was $832.3 million at Ligand Pharmaceuticals, up from $331.6 million in the prior quarter.
  • Across five years, Current Assets topped out at $832.3 million in Q4 2025 and bottomed at $220.4 million in Q3 2022.
  • The 5-year median for Current Assets is $328.2 million (2023), against an average of $358.5 million.
  • The largest annual shift saw Current Assets plummeted 52.42% in 2021 before it soared 151.02% in 2025.
  • A 5-year view of Current Assets shows it stood at $464.8 million in 2021, then plummeted by 43.28% to $263.6 million in 2022, then decreased by 9.93% to $237.4 million in 2023, then skyrocketed by 39.65% to $331.6 million in 2024, then skyrocketed by 151.02% to $832.3 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Current Assets are $832.3 million (Q4 2025), $331.6 million (Q4 2024), and $368.9 million (Q1 2024).